دورية أكاديمية
Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer.
| العنوان: | Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer. |
|---|---|
| المؤلفون: | McLouth LE; Department of Behavioral Science, Markey Cancer Center, Center for Health Equity Transformation, University of Kentucky College of Medicine, Lexington, Kentucky, USA., Gabbard J; Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA., Levine BJ; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.; Department of Social Sciences and Health Policy and Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Golden SL; Goldsmith Research Group, Winston-Salem, North Carolina, USA., Lycan TW; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.; Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Petty WJ; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.; Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Weaver KE; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.; Department of Social Sciences and Health Policy and Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. |
| المصدر: | Journal of palliative medicine [J Palliat Med] 2023 Jun; Vol. 26 (6), pp. 831-836. Date of Electronic Publication: 2023 Mar 13. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 9808462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-7740 (Electronic) Linking ISSN: 15577740 NLM ISO Abbreviation: J Palliat Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c1998- |
| مواضيع طبية MeSH: | Lung Neoplasms*/pathology , Carcinoma, Non-Small-Cell Lung*/therapy , Carcinoma, Non-Small-Cell Lung*/pathology, Humans ; Palliative Care ; Prognosis ; Outpatients ; Immunotherapy |
| مستخلص: | Background and Objectives: This study describes patients' prognostic awareness and palliative care use in the setting of immunotherapy for metastatic non-small cell lung cancer (mNSCLC). Design: We surveyed 60 mNSCLC patients receiving immunotherapy at a large academic medical center; conducted follow-up interviews with 12 survey participants; and abstracted palliative care use, advance directive completion, and death within a year of survey completion from the medical record. Results: Forty seven percent of patients surveyed thought they would be cured; 83% were not interested in palliative care. Interviews suggested oncologists emphasized therapeutic options when discussing prognosis and that commonly used descriptions of palliative care may exacerbate misperceptions. Only 7% had received outpatient palliative care and 8% had an advance directive a year after the survey; only 16% of the 19 patients who died had received outpatient palliative care. Conclusions: Interventions are needed to facilitate prognostic discussions and outpatient palliative care during immunotherapy. Clinical Trial Registration Number NCT03741868. |
| References: | Curr Oncol. 2018 Oct;25(5):e480-e485. (PMID: 30464700) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) Qual Health Res. 2005 Nov;15(9):1277-88. (PMID: 16204405) Oncologist. 2021 Aug;26(8):e1480-e1482. (PMID: 33844365) J Clin Oncol. 2011 Jun 10;29(17):2319-26. (PMID: 21555700) Palliat Med. 2004 Sep;18(6):525-42. (PMID: 15453624) Cancer. 2014 Jan 15;120(2):278-85. (PMID: 24122784) Health Expect. 2017 Oct;20(5):1073-1080. (PMID: 28261901) J Palliat Care. 2018 Jul;33(3):143-148. (PMID: 29790421) Transl Lung Cancer Res. 2022 Mar;11(3):432-439. (PMID: 35399575) J Clin Oncol. 2022 Feb 20;40(6):626-634. (PMID: 34985932) PLoS One. 2019 Aug 15;14(8):e0219074. (PMID: 31415570) Clin Lung Cancer. 2020 May;21(3):255-263.e4. (PMID: 31917067) J Palliat Med. 2019 May;22(5):508-516. (PMID: 30632886) J Pain Symptom Manage. 2019 Sep;58(3):460-464. (PMID: 31128230) J Oncol Pract. 2017 Sep;13(9):e703-e711. (PMID: 28783424) Am J Hosp Palliat Care. 2013 Mar;30(2):172-7. (PMID: 22531150) |
| معلومات مُعتمدة: | K23 AG070234 United States AG NIA NIH HHS |
| فهرسة مساهمة: | Keywords: immunotherapy; nivolumab; non-small cell lung cancer; palliative care; pembrolizumab; treatment expectations |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03741868 |
| تواريخ الأحداث: | Date Created: 20230313 Date Completed: 20230607 Latest Revision: 20240603 |
| رمز التحديث: | 20240603 |
| مُعرف محوري في PubMed: | PMC10277982 |
| DOI: | 10.1089/jpm.2022.0352 |
| PMID: | 36912809 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-7740 |
|---|---|
| DOI: | 10.1089/jpm.2022.0352 |